P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Selinexor for the treatment of multiple myeloma.
TL;DR: Selinexor represents a next-generation-novel agent with an innovative mechanism of action that marks a significant advance in the treatment of heavily pretreated MM patients, and ongoing studies investigate its therapeutic potential also in earlier lines of therapy.
Journal Article
Targeting proteasome inhibition in hematologic malignancies.
TL;DR: Recent studies demonstrate that PS-341, peptide boronate, has remarkable anti-tumor activity in preclinical and clinical studies, not only in multiple myeloma but also in other malignancies.
Journal ArticleDOI
Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie-Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +20 more
TL;DR: VMP was well tolerated, with patients remaining on VMP therapy for a median of 46 weeks versus 39 weeks with MP, and a statistically significant survival benefit for VMP versus MP after a median follow-up of 25.9 months.
Journal ArticleDOI
Anaemia in pregnancy is associated with advanced HIV disease.
Vikesh Nandlal,Dhayendre Moodley,Anneke Grobler,J.S. Bagratee,Niren R. Maharaj,Paul G. Richardson +5 more
TL;DR: In conclusion, anaemia was most common among women in the advanced stage of HIV infection (CD4<200 cells/mm3) and there was no evidence of an association between ZDV or triple ARVs and anaemia.
Journal ArticleDOI
Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data
Paul G. Richardson,Craig C. Hofmeister,Cara A. Rosenbaum,Myo Htut,David H. Vesole,Jesus G. Berdeja,Michaela Liedtke,Ajai Chari,Stephen D. Smith,Daniel Lebovic,Deborah Berg,Eileen Liao,Neeraj Gupta,Alessandra Di Bacco,Jose Estevam,Ai-Min Hui,Rachid Baz +16 more
TL;DR: The results of a phase 1/2 study of twice-weekly oral MLN9708 plus len-dex, conducted in collaboration with the Multiple Myeloma Research Consortium, of safety, tolerability, and the recommended phase 2 dose (RP2D) are reported.